---
category: news
title: "Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial"
excerpt: "DSP-0038 is the third molecule created using Exscientia's Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma to treat obsessive-compulsive disorder,"
publishedDateTime: 2021-05-13T07:37:00Z
originalUrl: "https://www.tmcnet.com/usubmit/2021/05/13/9368372.htm"
webUrl: "https://www.tmcnet.com/usubmit/2021/05/13/9368372.htm"
type: article
quality: 0
heat: 0
published: false

provider:
  name: TMCnet
  domain: tmcnet.com

topics:
  - AI in Healthcare
  - AI

secured: "TMn99XrHghsUOh2lJZY9njE9deuIBOwI43KlCzaLRt8HwST2+uMkTCpDYASuV/AUfdv5fpryJTxFM+fW7sfw+pYP4XLf0mKGQ+hrevBsIewb7rz/LdYK7p6TRKx+2fd5eeFNVEAU1/2iaQlCKgQrv+1dmMny82zf2qCjTU2w/DkWfWbNgxQOX3y9zZMwOdGNN0BWDfcKcP9Jfnm55SnZb9cjuQ5Llz7H0ef0TOuQx6EJJ3Q08dMh3bNiBcwxAyCdQ0WF6yPyhFxFeiaV15Itzdeg37m7sngtesvKJjC9DoHtZE1jMiPMZQEOzRSBh8Fw6CMFzM87a6FTfHcInwPMWUiEs4/9UiVGBoA+5xuwASI=;XbjOphiEKtZfCSpErpYybA=="
---

